hi-c
(2)
Arima Genomics
Arima Genomics is a Carlsbad, California biotech commercializing Hi-C technology - sequencing methods that reveal the 3D structure of the genome. Its research kits help scientists assemble chromosome-scale genomes and study chromatin architecture, while its clinical brand Aventa Genomics turns the same proximity-ligation chemistry into FFPE-friendly cancer tests for fusions, rearrangements, and other structural variants conventional NGS often misses.
Tom Willis
Tom Willis, PhD, is a genomics entrepreneur with more than 20 years of company-building experience who became CEO of Arima Genomics in June 2025. A Yale and Stanford physicist turned biotech serial founder, he co-invented Molecular Inversion Probe technology, built two genomics companies from the ground up - ParAllele BioScience (acquired by Affymetrix) and Sequenta (whose ClonoSEQ assay became NCCN-standard for leukemia and lymphoma residual disease testing) - then spent a decade as Venture Partner at Illumina Ventures before stepping in to lead Arima, a company pioneering 3D genomics for cancer diagnostics.